HR+/HER2- BC patients are usually considered less sensitive to chemotherapy, and only about 10 to 20% of luminal-type patients can achieve pathological complete response (pCR) with neoadjuvant chemotherapy (35). The gene discussed is ERBB2; the disease is breast cancer.